

Mungo Park

Position/Department/Division/Institution/Organization

Founder and Chair, Innovator Capital Limited (ICL)

Country

United Kingdom

Career history

- 1973 – 1974 **Bache & Co.**, London
Institutional Equity Sales
Reported to Alfred Elbrick, and worked with him covering English, Scottish and Irish institutional investors. We both left the firm at the same time. I needed stock exchange experience.
- 1974 - 1975 **Kitcat & Aitken**, London
London Stock Exchange and Eurobonds
Reported to Max Neilsen, spent a year working on the floor of the stock exchange and a year working in the Eurobond Department. Obtained the experience and went to America to work again with Alfred Elbrick.
- 1975 - 1979 **Alex. Brown & Sons**, Baltimore, MD, USA
Institutional Equity Sales, ICT, Biotech and Pharma
Covered institutional investors on a Pan European basis, interacting daily with trading, research, syndicate and corporate executives.
- 1979 - 1981 **Dillon Read & Co.**, London & New York
Institutional Equity Sales and Research, ICT
Reported to Evan Galbraith and launched Gartner Group Research in Europe, pure ICT investment banking. Gartner became the world's leading independent ICT research house. Originated and implemented hugely successful, first of its kind business model. Galbraith appointed U.S. Ambassador to France, control of my division moved to New York – became unworkable.

- 1981 - 1987 **Wertheim & Co.**, London & New York
Opened London Office, Investment Banking, ICT, Biotech and Pharma
Recruited by Gerry Kaminsky. Built the operation from scratch with novel marketing approach given we were the 43rd U.S. bank to open in London. Financially very rewarding, as the crash of 1987 came and with 14 years of total commitment to investment banks, I decided to work as an independent adviser.
- 1987 - 1995 **Independent Adviser**, London
Medeva Plc.
Active Analysis
Invested in and advised a number of companies. Of particular interest was working with Bernard Taylor, ex CEO of GSK, on a novel vaccine manufacturing platform and setting up new pharmaceutical company called Medeva Plc. Also set up a software company, doing big data analysis. Sold company to a U.S. Government contractor.
- 1995 - 1997 **Cowen & Co.**, London, Boston & New York
Investment Banking, ICT, Biotech and Pharma
Recruited again by Gerry Kaminsky. Cowen was the top healthcare IPO firm on Wall Street and a leader in ICT. Gerry wanted my experience in the business and the sector. U.S. inv. Banking began to lose its way and my growing conviction that the model lacked integrity made me look elsewhere to implement a new business model. Nomura approached me and offered the opportunity.
- 1997 - 1999 **Nomura International Plc**, London
Investment Banking, Biotech, Pharma and ICT
As Head of Corporate Finance, worldwide, for three sectors, implemented new investment banking model. Built team from scratch, with Principal Finance strategy and integrated it with traditional disciplines under the same P&L. We put our money at risk alongside the investment clients. Thereby aligning interests. Raised over \$500 million for cancer related projects. Left Nomura after Russia defaulted on western debt, costing Nomura \$3billion and Tokyo HQ wanting to revert to old business model.

1999 - 2001

Portfin.com Limited, London

Fintech Start Up

Set up internet company to provide “white label” platform for small to medium sized brokers and investment managers to offer to their customers. I chose the wrong partner and resigned from the company. (More information on request)

2001 - 2003

Columbus Asset Management London

Navigator Asset Management (Chair)

Worked with both companies to develop novel - in the UK - corporate finance models. One a revenue-based royalty model to provide funding for Bio/Pharma companies, the other, a non-toxic version of the American equity line of credit.

2003 - Present

Innovator Capital Limited (“ICL”), (Founder and Chair)

Investment Banking, Health and Sustainability Technology Innovation

ICL is a London based specialist investment bank, founded by Mungo in 2003. The focus is on acceleration of sustainable technology innovation; technologies which rapidly impact the causes and consequences of climate change. ICL provides, corporate finance, M&A, technology transfer, intellectual property and strategic advisory services to the innovators.

ICL was originally founded to advise Life-Science companies; by 2004 Mungo concluded that he would not find a cure for asthma in his lifetime so set about looking for technologies that could address air pollution, an aggravator of paediatric asthma, particularly from heavy-duty vehicles in urban areas. It then became obvious that sustainable, resource efficient and clean technologies in air, water, food and energy were essential to quality of life. ICL added sustainable technologies to its area of specialisation; a prophylactic and therapeutic approach to some of world’s greatest threats.

In 2007 Mungo and His Serene Highness Prince Albert founded CleanEquity® Monaco; which is now one of the world’s premier, sustainable technology conferences. Over 600 technologies every year are sourced; 30 of them, meeting strict, key criteria, are selected to attend and potentially, be

clients for ICL. To date, some 350 technologies, from over 30 countries, have been shown to interested parties from around the world.

In 2011, determined to raise awareness of sustainability further, ICL involved the Nobel name in CleanEquity® Monaco. Working closely with the newly created Nobel Sustainability® Trust and with His Serene Highness, the Nobel Sustainability® Fund was launched in 2016. It is the world's first multi-phase, multi-technology and multi-geography sustainable technology fund.

Other appointments

2006 - 2019	CDTi, Inc. (NASDAQ, sustainable technology innovation company) California, Director, Chair and Chair of Audit Committee
2008 - 2017	Heart Metabolics, Director
2010 - 2014	Climate Change Forum participant, UK Minister, Energy and Climate Change
2019 - Present	Director, MagneGas, sustainable technology innovation company, Ireland Limited

Areas of expertise

Forty-five years of experience in investment banking/advisory. Industry specialisation includes the United Nations Sustainable Development Goals with a particular focus on technological innovation in sustainability, health, and information and communication technology (ICT).